A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumors|HER2-positive Breast Cancer
Interventions: DRUG: ZN-A-1041 50mg BID|DRUG: ZN-A-1041 100mg BID|DRUG: ZN-A-1041 200mg BID|DRUG: ZN-A-1041 400mg BID|DRUG: ZN-A-1041 600mg BID|DRUG: ZN-A-1041 800mg BID|DRUG: ZN-A-1041 1000mg BID|DRUG: ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1b|DRUG: ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1b|DRUG: ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1b|DRUG: ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1c|DRUG: ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1c|DRUG: ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1c
Sponsor: Suzhou Zanrong Pharma Limited